$103.4 M

MBRX Mkt cap, 26-Apr-2021
Moleculin Biotech Net income (FY, 2020)-17.3 M
Moleculin Biotech EBIT (FY, 2020)-19.7 M
Moleculin Biotech Cash, 31-Dec-202015.2 M
Moleculin Biotech EV88.4 M

Moleculin Biotech Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

R&D expense

4.5m9.7m11.0m12.8m

General and administrative expense

4.1m5.2m6.3m6.8m

Operating expense total

8.6m15.0m17.5m19.5m

Depreciation and amortization

18.0k68.0k199.0k200.0k

EBIT

(8.7m)(15.0m)(17.5m)(19.7m)

Interest expense

13.0k

Interest income

4.0k13.0k

Pre tax profit

(13.4m)(17.4m)

Income tax expense

(229.0k)

Net Income

(9.8m)(11.9m)(13.2m)(17.3m)

EPS

(0.5)(0.5)(0.3)

Moleculin Biotech Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

7.7m7.1m10.7m15.2m

Prepaid Expenses

588.0k840.0k2.7m2.0m

Current Assets

8.3m8.0m13.5m17.2m

PP&E

33.0k463.0k316.0k483.0k

Goodwill

11.1m

Total Assets

19.5m19.6m25.2m29.0m

Accounts Payable

810.0k1.2m2.2m1.1m

Current Liabilities

2.2m3.9m3.6m2.9m

Long-term debt

276.0k159.0k

Total Debt

276.0k159.0k

Total Liabilities

2.4m5.3m9.7m11.3m

Common Stock

21.0k29.0k46.0k69.0k

Preferred Stock

Additional Paid-in Capital

31.6m40.6m55.1m74.7m

Retained Earnings

(14.5m)(26.4m)(39.6m)(56.9m)

Total Equity

17.1m14.3m15.6m17.8m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.1 x1.4 x1.6 x1.6 x

Moleculin Biotech Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(9.8m)(11.9m)(13.2m)

Depreciation and Amortization

18.0k68.0k199.0k200.0k

Accounts Payable

411.0k436.0k907.0k(1.0m)

Cash From Operating Activities

(7.3m)(12.2m)(17.2m)(17.8m)

Purchases of PP&E

(28.0k)(417.0k)(52.0k)(376.0k)

Cash From Investing Activities

(28.0k)(417.0k)(51.0k)(374.0k)

Cash From Financing Activities

10.1m12.0m20.9m22.5m

Net Change in Cash

2.7m(580.0k)3.6m4.4m

Interest Paid

3.0k5.0k1.0k

Income Taxes Paid

19.0k24.0k

Moleculin Biotech Ratios

USDFY, 2017

Financial Leverage

1.1 x